{"nctId":"NCT00057681","briefTitle":"Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents","startDateStruct":{"date":"2003-02"},"conditions":["Bipolar Disorder"],"count":379,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Lithium carbonate"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Valproate"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Risperidone"]}],"interventions":[{"name":"Lithium carbonate","otherNames":[]},{"name":"Valproate","otherNames":["Depakote"]},{"name":"Risperidone","otherNames":["Risperdal"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* DSM-IV criteria for bipolar I (manic or mixed) or mania for at least 4 weeks\n* CGAS less than or equal to 60\n* Good physical health\n\nExclusion Criteria:\n\n* Schizophrenia or any pervasive developmental disorder\n* Major medical or neurological disease\n* History of addiction to illicit substances or alcohol or drug abuse within the last 4 weeks\n* IQ less than 70\n* Pregnancy or breast-feeding\n* Unacceptable methods of contraception\n* In-patient care at baseline","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Global Impressions-Bipolar Mania Improvement","description":"The Clinical Global Impressions-Bipolar (CGI-BP) assessment instrument measured improvement in mania, depression, and overall bipolar illness. The primary outcome measure was mania improvement, which measured the change in mania from baseline. Scores were 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"1.05"},{"groupId":"OG001","value":"2.73","spread":"1.08"},{"groupId":"OG002","value":"1.70","spread":"0.63"}]}]}]},{"type":"SECONDARY","title":"Modified Side Effects Form for Children and Adolescents","description":"The Modified Side Effects Form for Children and Adolescents includes 62 potential side effects, with measures of frequency and severity for each item. Frequencies are 0=not present, 1=1-2 days, 2=3-4 days, 3=5-7 days. Severity scores are 0=not present, 1=mild (does not interfere with functioning), 2=moderate (some interference with functioning), 3=severe (functioning is significantly impaired because of side effects). Items for cardiovascular, gastrointestinal, central nervous system, ocular, mouth and nose, genito urinary, dermatology, musculo-skeletal, and other side effects are included. For analyses, side effects that were reported at any frequency and a severity of 2 or greater were considered present.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.11","spread":"3.54"},{"groupId":"OG001","value":"4.95","spread":"3.29"},{"groupId":"OG002","value":"3.70","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"K-SADS Mania Rating Scale","description":"The K-SADS Mania Rating Scale (KMRS) is comprised of 15 items modified from WASH-U-KSADS items. The individual items are scored on a 1-6 severity scale and then these item scores are summed to create an overall KMRS score. Guidelines for interpretation are as follows: 0-11 = no or minimal mania, 12-17 = mild mania, 18-25 = moderate mania, 26+ = marked or worse mania. The maximum possible score is 64.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.06","spread":"12.11"},{"groupId":"OG001","value":"26.31","spread":"11.71"},{"groupId":"OG002","value":"14.58","spread":"7.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":137},"commonTop":[]}}}